We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-7.9%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
-$202M
Cap. Flow
+$27.4M
Cap. Flow %
1.97%
Top 10 Hldgs %
51.89%
Holding
98
New
17
Increased
22
Reduced
21
Closed
23

Top Buys

Rank Stock Value
1
BBNX
Beta Bionics
BBNX
+$63.3M
2
NVCR icon
NovoCure
NVCR
+$63.2M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$56M
4
STAA icon
STAAR Surgical
STAA
+$51.4M
5
HOLX
Hologic
HOLX
+$20M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$29.3M
2
AXGN icon
Axogen
AXGN
+$27.2M
3
AZN icon
AstraZeneca
AZN
+$26.8M
4
QDEL icon
QuidelOrtho
QDEL
+$24.4M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$23.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
76
Alnylam Pharmaceuticals
ALNY
$29.3B
– –
-76,800
Closed -$18.1M
AZN icon
77
AstraZeneca
AZN
$250B
– –
-204,500
Closed -$26.8M
BLCO icon
78
Bausch + Lomb
BLCO
$5.99B
– –
-120,500
Closed -$2.18M
CRNX icon
79
Crinetics Pharmaceuticals
CRNX
$8.92B
– –
-85,000
Closed -$4.35M
CSTL icon
80
Castle Biosciences
CSTL
$979M
– –
-252,917
Closed -$6.74M
ELV icon
81
Elevance Health
ELV
$85.5B
– –
-550
Closed -$203K
ELVN icon
82
Enliven Therapeutics
ELVN
$4.43B
– –
-75,405
Closed -$1.7M
ESTA icon
83
Establishment Labs
ESTA
$2.28B
– –
-59,400
Closed -$2.74M
GSK icon
84
GSK
GSK
$106B
– –
-10,110
Closed -$342K
LLY icon
85
Eli Lilly
LLY
$1.06T
– –
-11,658
Closed -$9M
MDXH icon
86
MDxHealth
MDXH
$23.7M
– –
-851,688
Closed -$2.02M
PCVX icon
87
Vaxcyte
PCVX
$8.64B
– –
-99,050
Closed -$8.11M
QDEL icon
88
QuidelOrtho
QDEL
$838M
– –
-547,082
Closed -$24.4M
RCKT icon
89
Rocket Pharmaceuticals
RCKT
$394M
– –
-271,659
Closed -$3.41M
REGN icon
90
Regeneron Pharmaceuticals
REGN
$80.8B
– –
-2,300
Closed -$1.64M
REPL icon
91
Replimune Group
REPL
$1.01B
– –
-262,500
Closed -$3.18M
TAK icon
92
Takeda Pharmaceutical
TAK
$55.7B
– –
-1,180,000
Closed -$15.6M
THC icon
93
Tenet Healthcare
THC
$21.1B
– –
-2,027
Closed -$256K
VCEL icon
94
Vericel Corp
VCEL
$2.31B
– –
-80,696
Closed -$4.43M
VRDN icon
95
Viridian Therapeutics
VRDN
$2.67B
– –
-45,500
Closed -$872K
WGS icon
96
GeneDx Holdings
WGS
$2.3B
– –
-4,000
Closed -$307K
ONC
97
BeOne Medicines Ltd
ONC
$39.4B
– –
-1,150
Closed -$212K
WHWK
98
Whitehawk Therapeutics
WHWK
$271M
– –
-333,227
Closed -$1.05M
1 2 3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Soleus Capital Management held 98 positions worth $1.39B, down 13% from $1.59B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Soleus Capital Management's Q1 2025 filing shows 17 new, 22 increased, 21 reduced and 23 closed positions. Its largest new stake was Beta Bionics: 3,395,341 shares worth $41.6M. The largest sale was Teva Pharmaceuticals, an estimated $29.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 83% a quarter earlier.

  • Soleus Capital Management's largest Q1 2025 buy was Beta Bionics: 3,395,341 shares worth $41.6M.
  • Soleus Capital Management added most to NovoCure in Q1 2025, an estimated $63.2M increase.
  • Soleus Capital Management's biggest Q1 2025 reduction was Teva Pharmaceuticals, cutting an estimated $29.3M.
  • Soleus Capital Management fully exited AstraZeneca in Q1 2025, selling an estimated $26.8M.
  • Soleus Capital Management's ten largest holdings make up 52% of its $1.39B portfolio in Q1 2025.
  • Soleus Capital Management opened 17 new positions and closed 23 in Q1 2025.
  • Soleus Capital Management's portfolio value fell 13% quarter-over-quarter to $1.39B.

Based on Soleus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.